Global Bi-Specific MAbS Market Report 2024

Bi-Specific MAbS Global Market Report 2024 – By Type (Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab), By Product Type (In Vivo, In Vitro), By Indication (Cancer, Hemophilia A, Ophthalmic), By End Use (Hospitals, Research Institutes, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

Bi-Specific MAbS Global Market Report 2024

Starting Price : $5000.00 $4000.00 | Pages : 175 | Published : October 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Bi-Specific MAbS Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN

Bi-Specific MAbS Market Definition

Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumour immunotherapy.

The main types of bi-specific are catumaxomab (removal), blinatumomab, duligotumab, and SAR 156597. Catumaxomab is a rat-mouse hybrid monoclonal antibody used to treat malignant ascites, a condition that occurs in people who have metastasizing cancer. The various product types including in vivo, and in vitro are used for the treatment of cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases, and others. The bispecific monoclonal antibodies are used by hospitals, research institutes, and others.

Bi-Specific MAbS Market Segmentation

The bi-specific mabs market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Global Bi-Specific MAbS Market Size 2023 to 2028: Graph

Bi-Specific MAbS Market Size 2024 And Growth Rate

The bi-specific mabs market size has grown rapidly in recent years. It will grow from $8.81 billion in 2023 to $10.25 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to increased healthcare expenditure, increased funding and government initiatives.

Bi-Specific MAbS Market Growth Forecast

The bi-specific mabs market size is expected to see rapid growth in the next few years. It will grow to $16.9 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to an increasing prevalence of cancer, an increasing aging population and an increase in the prevalence of chronic diseases. Major trends in the forecast period include focus on technological advancements, product innovation, focus on artificial intelligence, investment in targeted and combination therapy and strategic partnerships.

Bi-Specific MAbS Market Driver: Impact Of Increasing Cancer Prevalence On The Bi-Specific Mabs Market

The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective than monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression. For instance, in 2023, according to the Cancer Facts & Figures 2023 report published by the American Cancer Society (ACS), a US-based voluntary health organization, there will be an estimated 609,820 cancer related deaths in the USA. Therefore, a rising number of chronic diseases, including cancer, is anticipated to propel the demand for bi-specific MAbs to treat these diseases effectively.

Bi-Specific MAbS Market Driver: Government Support In Healthcare Research And Development Boosting The Bi-Specific Mabs Market

Government initiatives for research and development in healthcare are expected to propel the growth of the growth of the Bi-Specific MAbS market going forward. Government initiatives refer to specific actions, programs, policies, or projects undertaken by government authorities to address specific issues, achieve certain goals, or create positive changes in society. For Instance, in August 2023, The Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services (HHS) collaborated with Regeneron Pharmaceuticals Inc, a US-based science and technology company for the development of a next-generation monoclonal antibody therapy for the prevention of SARS-CoV-2 infection as part of the U.S. Department of Health and Human Services' 'Project NextGen.' The agreement entails up to 70% of funding from the U.S. government for Regeneron's costs in clinical development activities for the monoclonal antibody therapy, with an estimated contract value of approximately $326 million. Therefore, the government initiatives for research and development in healthcare drives the the Bi-Specific MAbS market.

Global Bi-Specific MAbS Market Major Players

Major companies operating in the bi-specific mabs market report are F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Innovent Biologics, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, EpimAb Biotherapeutics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, Enteris BioPharma, BioMarin Pharmaceuticals, Parexel, Hikma Pharmaceuticals PLC, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

Global Bi-Specific MAbS Market Restraint: Growing Popularity Of Alternative Cancer Therapies Implications For The Bi-Specific Mabs Market

The availability of various alternative treatment methods for cancer is expected to limit the growth of the bispecific monoclonal antibodies market. Alternative cancer treatment therapies and methods used for the treatment of cancer including dietary treatments, acupuncture, homeopathy, and herbal remedies are gaining popularity in recent years attributed to side effects of chemotherapeutic anticancer agents. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many of the herbs used in Ayurveda have anti-cancer properties, for example, andrographispaniculata. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source, and developing nations are using the benefits of natural compounds for therapeutic purposes. Therefore, this affects the biologic sales and hence impacts the bi-specific MAbS market. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027, growing at a CAGR of 14% during the forecast period. The less expensive alternative medicines increase competition for the biologics market, thereby, hindering the growth of the bi-specific MAbs market shortly.

Global Bi-Specific MAbS Market Trend: Strategic Collaborations And Partnerships Fuel Growth In The Bi-Specific Mabs Market

Companies in the bi-specific MAbS market are increasingly investing in various strategic initiatives, such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. A strategic collaboration is a cooperative partnership between two or more organizations to achieve common goals or objectives. For instance, in October 2022, Gilead Sciences, a US-based biopharmaceutical company and MacroGenics, a US-based biopharmaceutical company, entered into an exclusive collaboration to develop MGD024, a bispecific antibody targeting CD123 and CD3 using MacroGenics' DART platform, along with two other bispecific research programs. The collaboration grants Gilead an exclusive option to license MGD024, which has the potential to treat various hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is designed to minimize cytokine-release syndrome (CRS) and allow intermittent dosing, potentially leading to more patient-friendly treatment and improved clinical outcomes for individuals with AML and MDS.

Global Bi-Specific MAbS Market Trend: Advanced Technologies Transforming The Bi-Specific Mabs Market

Major companies operating in Bi-Specific MAbS market are introducing advanced technologies such as the bispecific monoclonal antibodies to gain a competitive edge in the market. Bi-Specific Monoclonal Antibodies (mAbs) are a type of artificial protein that can simultaneously bind to two different types of antigens. These antibodies are designed to target specific molecules present on the surface of cells. For instance, in September 2021, Amgen, a US-based biopharmaceutical company and Boehringer Ingelheim, a Germany-based pharmaceutical company are collaborating on a Phase II-ready project. Convincing clinicians to transition between bispecific mAbs would necessitate significant improvements in efficacy or safety. Alternative strategies, such as initiating treatment at an earlier stage, modifying the administration method, or adjusting the treatment frequency, are feasible but demand timely strategic planning from the developers. Bispecific mAb is poised not only to outperform its competitors but also to potentially encroach upon the market share of CAR-T cell therapies in the relapsed or refractory multiple myeloma sector.

Bi-Specific MAbS Market Merger And Acquisition: Takeda's Strategic Acquisition: Expanding Bispecific Antibody Technology

In March 2021, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company acquired Maverick Therapeutics for an undisclosed amount. With this acquisition, Takeda aims at developing bispecific antibody technology and patients would benefit from the expansion of resources and experience and accelerate development of our T-cell engager platform and pipeline of innovative bispecific immunotherapies. Maverick Therapeutics is a US-based company that offers biospecific MAbs..

Regional Analysis For The Global Bi-Specific MAbS Market

North America was the largest region in the bi-specific MAbS market in 2023. The regions covered in the bi-specific mabs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the bi-specific mabs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of trifunctional antibodies, chemically linked Fabs, and bispecific T cell engagers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The bi-specific MAbs or bispecific monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides bi-specific MAbs or bispecific monoclonal antibodies market statistics, including bi-specific MAbs or bispecific monoclonal antibodies industry global market size, regional shares, competitors with a bi-specific MAbs or bispecific monoclonal antibodies market share, detailed bi-specific MAbs or bispecific monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the bi-specific MAbs or bispecific monoclonal antibodies industry. This bi-specific MAbs or bispecific monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Bi-Specific MAbS Report Forecast And Analysis
Report AttributeDetails
Market Size Value In 2024 $10.25 billion
Revenue Forecast In 2033 $16.9 billion
Growth Rate CAGR of 13.3% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab
2) By Product Type: In Vivo, In Vitro
3) By Indication: Cancer, Hemophilia A, Ophthalmic
4) By End Use: Hospitals, Research Institutes, Other End-Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Additional countries that can be covered in the report for an additional fee: Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled F. Hoffmann-La Roche AG; Amgen Inc; Johnson & Johnson; Innovent Biologics; Sino Biological Inc; Kyowa Kirin; Zai Lab; Alphamab Oncology; Celldex Therapeutics; Biocon; EpimAb Biotherapeutics; ABL Bio; Takeda pharmaceuticals; Innovent Biologics; EpimAb Biotherapeutics; Merck & Co Inc; Eli Lilly Company Inc.; AbbVie Inc; Bayer AG; Pfizer Inc; Novartis AG; GlaxoSmithKline; AstraZeneca; Cytiva; Bristol Myers Squibb; AbCellera; Enteris BioPharma; BioMarin Pharmaceuticals; Parexel; Hikma Pharmaceuticals PLC; Sanofi S.A.; Novo Nordisk A/S; BBI Solutions; Aspen Pharmacare; Amoun Pharmaceuticals CO Ltd; Baxter International; Cipla Medpro South Africa
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Bi-Specific MAbS Market Characteristics

    3. Bi-Specific MAbS Market Trends And Strategies

    4. Bi-Specific MAbS Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Bi-Specific MAbS Market Size and Growth

    5.1. Global Bi-Specific MAbS Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Bi-Specific MAbS Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Bi-Specific MAbS Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Bi-Specific MAbS Market Segmentation

    6.1. Global Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Catumaxomab (Removab)

    Blinatumomab

    Duligotumab

    SAR 156597

    6.2. Global Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    In Vivo

    In Vitro

    6.3. Global Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Cancer

    Autoimmune Diseases

    Inflammatory Diseases

    Infectious Diseases

    Microbial Diseases

    Other Indications

    6.4. Global Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Research Institutes

    Other End-Users

    7. Bi-Specific MAbS Market Regional And Country Analysis

    7.1. Global Bi-Specific MAbS Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Bi-Specific MAbS Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Bi-Specific MAbS Market

    8.1. Asia-Pacific Bi-Specific MAbS Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Bi-Specific MAbS Market

    9.1. China Bi-Specific MAbS Market Overview

    9.2. China Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Bi-Specific MAbS Market

    10.1. India Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Bi-Specific MAbS Market

    11.1. Japan Bi-Specific MAbS Market Overview

    11.2. Japan Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Bi-Specific MAbS Market

    12.1. Australia Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Bi-Specific MAbS Market

    13.1. Indonesia Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Bi-Specific MAbS Market

    14.1. South Korea Bi-Specific MAbS Market Overview

    14.2. South Korea Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Bi-Specific MAbS Market

    15.1. Western Europe Bi-Specific MAbS Market Overview

    15.2. Western Europe Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Bi-Specific MAbS Market

    16.1. UK Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Bi-Specific MAbS Market

    17.1. Germany Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Bi-Specific MAbS Market

    18.1. France Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Bi-Specific MAbS Market

    19.1. Italy Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Bi-Specific MAbS Market

    20.1. Spain Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Bi-Specific MAbS Market

    21.1. Eastern Europe Bi-Specific MAbS Market Overview

    21.2. Eastern Europe Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Bi-Specific MAbS Market

    22.1. Russia Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Bi-Specific MAbS Market

    23.1. North America Bi-Specific MAbS Market Overview

    23.2. North America Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Bi-Specific MAbS Market

    24.1. USA Bi-Specific MAbS Market Overview

    24.2. USA Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Bi-Specific MAbS Market

    25.1. Canada Bi-Specific MAbS Market Overview

    25.2. Canada Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Bi-Specific MAbS Market

    26.1. South America Bi-Specific MAbS Market Overview

    26.2. South America Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Bi-Specific MAbS Market

    27.1. Brazil Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Bi-Specific MAbS Market

    28.1. Middle East Bi-Specific MAbS Market Overview

    28.2. Middle East Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Bi-Specific MAbS Market

    29.1. Africa Bi-Specific MAbS Market Overview

    29.2. Africa Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Bi-Specific MAbS Market Competitive Landscape And Company Profiles

    30.1. Bi-Specific MAbS Market Competitive Landscape

    30.2. Bi-Specific MAbS Market Company Profiles

    30.2.1. F. Hoffmann-La Roche AG

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Amgen Inc

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Johnson & Johnson

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Innovent Biologics

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Sino Biological Inc

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Bi-Specific MAbS Market Other Major And Innovative Companies

    31.1. Kyowa Kirin

    31.2. Zai Lab

    31.3. Alphamab Oncology

    31.4. Celldex Therapeutics

    31.5. Biocon

    31.6. EpimAb Biotherapeutics

    31.7. ABL Bio

    31.8. Takeda pharmaceuticals

    31.9. Innovent Biologics

    31.10. EpimAb Biotherapeutics

    31.11. Merck & Co Inc

    31.12. Eli Lilly Company Inc.

    31.13. AbbVie Inc

    31.14. Bayer AG

    31.15. Pfizer Inc

    32. Global Bi-Specific MAbS Market Competitive Benchmarking

    33. Global Bi-Specific MAbS Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Bi-Specific MAbS Market

    35. Bi-Specific MAbS Market Future Outlook and Potential Analysis

    35.1 Bi-Specific MAbS Market In 2028 - Countries Offering Most New Opportunities

    35.2 Bi-Specific MAbS Market In 2028 - Segments Offering Most New Opportunities

    35.3 Bi-Specific MAbS Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Bi-Specific MAbS Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Global Bi-Specific MAbS Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: Asia-Pacific, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: China, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: India, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Japan, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Australia, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: Indonesia, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: South Korea, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: Western Europe, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: UK, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: Germany, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: France, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Italy, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Spain, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Eastern Europe, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: Russia, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: North America, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: USA, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: Canada, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: South America, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Brazil, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Middle East, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Africa, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 75: F. Hoffmann-La Roche AG Financial Performance
  • Table 76: Amgen Inc Financial Performance
  • Table 77: Johnson & Johnson Financial Performance
  • Table 78: Innovent Biologics Financial Performance
  • Table 79: Sino Biological Inc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Bi-Specific MAbS Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Global Bi-Specific MAbS Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: Asia-Pacific, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: China, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: India, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Japan, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Australia, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: Indonesia, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: South Korea, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: Western Europe, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: UK, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: Germany, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: France, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Italy, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Spain, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Eastern Europe, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: Russia, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: North America, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: USA, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: Canada, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: South America, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Brazil, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Middle East, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Africa, Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 75: F. Hoffmann-La Roche AG Financial Performance
  • Figure 76: Amgen Inc Financial Performance
  • Figure 77: Johnson & Johnson Financial Performance
  • Figure 78: Innovent Biologics Financial Performance
  • Figure 79: Sino Biological Inc Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the bi-specific MAbS market?

Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumour immunotherapy. For further insights on the bi-specific MAbS market, request a sample here

How will the bi-specific MAbS market drivers and restraints affect the bi-specific MAbS market dynamics? What forces will shape the bi-specific MAbS industry going forward?

The bi-specific MAbS market major growth driver - Impact Of Increasing Cancer Prevalence On The Bi-Specific Mabs Market. For further insights on the bi-specific MAbS market, request a sample here

What is the forecast market size or the forecast market value of the bi-specific MAbS market?

The bi-specific MAbS market size has grown rapidly in recent years. It will grow from $8.81 billion in 2023 to $10.25 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to increased healthcare expenditure, increased funding and government initiatives. The bi-specific MAbS market size is expected to see rapid growth in the next few years. It will grow to $16.9 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to an increasing prevalence of cancer, an increasing aging population and an increase in the prevalence of chronic diseases. Major trends in the forecast period include focus on technological advancements, product innovation, focus on artificial intelligence, investment in targeted and combination therapy and strategic partnerships. For further insights on the bi-specific MAbS market, request a sample here

How is the bi-specific MAbS market segmented?

The bi-specific MAbS market is segmented
1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab
2) By Product Type: In Vivo, In Vitro
3) By Indication: Cancer, Haemophilia A, Ophthalmic
4) By End Use: Hospitals, Research Institutes, Other End-UsersFor further insights on the bi-specific MAbS market,
request a sample here

Which region has the largest share of the bi-specific MAbS market? What are the other regions covered in the report?

North America was the largest region in the bi-specific MAbS market in 2023. The regions covered in the bi-specific MAbS market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the bi-specific MAbS market, request a sample here.

Who are the major players in the bi-specific MAbS market?

Major companies operating in the bi-specific MAbS market report are F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Innovent Biologics, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, EpimAb Biotherapeutics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, Enteris BioPharma, BioMarin Pharmaceuticals, Parexel, Hikma Pharmaceuticals PLC, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa For further insights on the bi-specific MAbS market, request a sample here.

What are the key trends in the bi-specific MAbS market?

Major trend in the bi-specific MAbS market - Strategic Collaborations And Partnerships Fuel Growth In The Bi-Specific Mabs Market. For further insights on the bi-specific MAbS market, request a sample here.

What are the major opportunities in the bi-specific MAbS market? What are the strategies for the bi-specific MAbS market?

For detailed insights on the major opportunities and strategies in the bi-specific MAbS market, request a sample here.

How does the bi-specific MAbS market relate to the overall economy and other similar markets?

For detailed insights on bi-specific MAbS market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the bi-specific MAbS industry?

For detailed insights on the mergers and acquisitions in the bi-specific MAbS industry, request a sample here.

What are the key dynamics influencing the bi-specific MAbS market growth? SWOT analysis of the bi-specific MAbS market.

For detailed insights on the key dynamics influencing the bi-specific MAbS market growth and SWOT analysis of the bi-specific MAbS industry, request a sample here.